Regeneron and bluebird bio announced a collaboration to apply their respective technology platforms to the discovery, development and commercialization of novel immune cell therapies for cancer. At the center of the initiative are the Regeneron’s VelociSuite platform technologies for the discovery and characterization of fully human antibodies as well as T cell receptors (TCRs) directed against tumor-specific proteins and peptides. bluebird bio will contribute its expertise in gene transfer and cell therapy to advance the jointly selected six initial targets (more might be identified in future); the companies will equally share the costs of R&D up to the point of submitting an Investigational New Drug application. Regeneron will also make a $100 million investment in bluebird bio common stock.

LEAVE A REPLY

Please enter your comment!
Please enter your name here